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Relationship between PK2 and number of Kupffer cells during
the progression of liver fibrosis in patients with HBV
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Background/aim: This study aimed to investigate the potential regulatory role of prokineticin 2 (PK2) in modulation of the number and
function of Kupffer cells (KCs) during the progression of liver fibrosis in patients with hepatitis B virus (HBV).
Materials and methods: We obtained liver tissue sections from 200 patients with HBV undergoing surgical resection in our hospital
between January 2013 and July 2016. Of these 200 tissue sections, 150 were fibrosis tissues and 50 were hepatocellular carcinoma
tissues. Immunohistochemical evaluations were performed to assess the expression levels of CD68 and PK2 in the sections. The clinical
parameters of these 200 patients were also analyzed.
Results: As a potential cytokine, PK2 was commonly expressed in KCs. In addition, a close correlation between PK2 and the number of
KCs during the progression of liver fibrosis in patients with HBV was found in this study.
Conclusion: PK2 is expressed in KCs and participates in the progression of liver fibrosis after HBV infection. As a potential cytokine,
PK2 modulates the number of KCs during fibrosis. Thus, PK2 most likely adjusts the number of M1 cells to modulate the role of KCs in
the progression of liver fibrosis after HBV infection.
Key words: Prokineticin 2, macrophage, Kupffer cells, liver fibrosis, hepatitis B virus infection

1. Introduction
Chronic hepatitis B (CHB) (defined as hepatitis B surface
antigen positive for at least 6 months) is a global health
issue, and the cumulative damage caused by inflammation
in the liver is an important inducement in the development
of cirrhosis and hepatocellular carcinoma (HCC) (1,2).
Liver fibrosis is an intrinsic response to CHB infection
and is described as the excess deposition of extracellular
matrix (ECM) preceding the development of cirrhosis and
HCC (3,4). There is evidence to show that liver fibrosis,
to some extent, and even cirrhosis can be reversed (3–5).
The host immunological response plays a key role
in the natural history of chronic HBV infection (6–9).
Immune cells, with the capacity to exert either injuryinducing or repair-promoting effects, play a key role in the
fibrotic cascade induced by CHB (6–9).
Monocytes are circulating precursors of tissue
macrophages, which help orchestrate adaptive immune
responses, and infiltrating monocytes have recently been
found linked to the development of liver fibrosis (3,8,9).
* Correspondence: liubusiness@163.com
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Macrophages play a vital role in maintaining
homeostasis, promoting and resolving inflammation,
repairing tissue, and causing liver fibrosis progression
or regression in the pathogenesis of acute or chronic
liver injury (6,9–11). Both monocytes and macrophages
play a dual role in modulating the level of transforming
growth factor beta 1 (TGF-β1) and other cytokines and
directly adjust the replenishment of the bone marrowderived monocyte/macrophage population during the
pathogenesis of liver fibrosis (7,9,11,12).
Kupffer cells (KCs) can activate hepatic stellate
cells through paracrine factors such as lipid peroxides,
TGF-β1, tumor necrosis factor-α (TGF-α), interleukin-6
(IL-6), platelet-derived growth factor (PDGF), gelatinase
B, reactive oxygen species (ROS), and nitric oxide (NO)
during the progression of fibrosis (5,7,8,11,12). The
plasticity of KCs enables them to alter their phenotypes
and functions in response to different microenvironmental
cues in the pathogenesis of liver fibrosis, which makes
them an attractive target (4,6,11).
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Prokineticin 2 (PK2), also known as Bombina variegata
8 (Bv8), belongs to the prokineticins, which is a new
family of secreted peptides characterized by a completely
conserved N-terminal hexapeptide (13). The conserved
structure endows PK2 with conserved bioactivities
including angiogenesis, neurogenesis, ingestive behaviors,
hormone release, gastrointestinal motility, circadian
rhythms, hyperalgesia, and blood cell function and
development (14–20). Previous studies reported that
PK2 has potent cytokine properties and can stimulate the
proliferation and mobilization of monocytes and their
differentiation into macrophages (13,15,20,21). It was also
reported that PK2 is expressed by KCs in the liver and is
likely to participate in the differentiation and modulation
of KCs function in an autocrine/paracrine manner (17).
This study aimed to investigate the potential regulatory
role of prokineticin 2 (PK2) in modulation of the number
and function of Kupffer cells (KCs) during the progression
of liver fibrosis in patients with hepatitis B virus (HBV).
2. Materials and methods
2.1. Liver tissue samples
Liver tissue samples consisting of 101 fibrosis, 49 cirrhosis,
and 50 tumor tissues were obtained from 200 patients with
HBV undergoing surgical resection between January 2013
and July 2016. Of these 200 patients, 182 were diagnosed
with HCC, 12 with cirrhosis, and 6 with hepatolithiasis.
In patients diagnosed with HCC, tumor samples were
obtained from within the tumor.
The 200 patients included in this study consisted of 153
males and 47 females with an average age of 50.5 ± 13.2
years. Access to this material was reviewed and approved by
the West China Hospital Sichuan University Clinical Trials
and Biomedical Ethics Committee. Three histological
staging systems (Ishak, METAVIR, and Knodell) were
used to evaluate the stage of fibrosis. The Ishak scoring
system classifies fibrosis using a 7-point scale as follows:
F0, no fibrosis; F1, fibrous expansion of some portal areas,
with or without short fibrous septa; F2, fibrous expansion
of most portal areas, with or without short fibrous septa;
F3, fibrous expansion of most portal areas with occasional
portal-to-portal bridging; F4, fibrous expansion of
portal areas with marked bridging (portal-to-portal as
well as portal-to-central); F5, marked bridging (portalportal and/or portal-central) with occasional nodules
(incomplete cirrhosis); F6, cirrhosis, probable or definite
(22). The METAVIR scoring system classifies fibrosis using
a 5-point scale: F0, no fibrosis; F1, portal fibrosis without
septa; F2, few septa; F3, numerous bridging septa without
cirrhosis; F4, cirrhosis (23). The Knodell scoring system
classifies fibrosis using a 4-point scale:F0, no fibrosis;
F1, fibrous portal expansion; F3, bridging fibrosis; F4,
cirrhosis (22). Cases were found of no significant fibrosis

(Ishak score 0–2, n = 49), significant fibrosis (Ishak score
3–6, n = 101), no cirrhosis (Ishak score 0–4, n = 101), and
cirrhosis (Ishak score 5–6, n = 49) (24).
All patients were positive for hepatitis B surface antigen
(HBsAg) for more than 6 months. Exclusion criteria
included the following: other hepatitis viruses (hepatitis
A, C, and E viruses), autoimmune hepatitis, drug-induced
hepatitis, hepatic echinococcosis, and liver fibrosis caused
by other etiologies. The detailed characteristics of these
patients are described in the Table.
2.2. Clinical data
Clinical information including sex, age, alanine
aminotransferase (ALT) level, aspartate aminotransferase
(AST) level, and platelet (PLT) count were obtained and
analyzed in this study.
2.3. Immunohistochemical (IHC) staining
Paraffin embedded liver sections were deparaffinized by 3
changes of xylene for 5 min and rehydrated in 3 changes of
100% ethanol for 5 min, 2 changes of 95% for 5 min, and
one change of 80% and 75% for 5 min, and then washed by
3 changes of distilled water for 3 min.
Antigen retrieval was performed at 121 °C for 2 min,
incubating in a citrate buffer, pH 6.0. Sections were allowed
to rest at room temperature (RT) for 20 min. Endogenous
peroxidase activity was inhibited by incubation with 3%
hydrogen peroxide (15 min, RT) and the nonspecific
sites were blocked with PBS/BSA 3% (40 min, RT).
PK2 and CD68 detection was performed by incubating
sections with primary antibodies overnight at 4 °C with
rabbit polyclonal anti-PK2 IgG (ab76747, dilution 1:100,
Abcam) and mouse monoclonal anti-CD68 IgG1 (ZM0060, dilution 1:50, ZSGB-BIO). Bovine serum albumin
(3%) was used instead of primary antibodies for negative
controls. Appropriate secondary antibodies were diluted
in appropriate diluent and incubated at RT for 1 h; DAB
was used for coloration (DAB Detection Kit, Gene Tech,
Shanghai, China). Positive IHC signals were indicated
by yellow, brown, or tan staining. Two experienced
pathologists examined the integrated slides independently.
Score evaluation was based on five randomly chosen fields
at 400-fold magnification for each slide.
The CD68 and PK2 immunoreactivity in tissue
sections was considered negative when no positive cells
were stained, weak when fewer than 30% of the cells
were positive, moderate when 30%–60% of the cells were
positive, and strong when more than 60% of cells were
stained as positive. The frequency of staining was thus
evaluated as 0, 1+, 2+, and 3+ for no, weak, moderate,
and strong immunoreactivity, respectively. The intensity
of staining was similarly evaluated as 0, 1+, 2+, and 3+
for no, weak, medium, and strong staining, respectively.
The IHC staining score was determined as the sum of the
frequency and intensity scores. If the histology scores of
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the two pathologists were different for the same sample, we
chose the mean as final result (25).
2.4. Statistical analysis
Data analysis was performed with IBM SPSS statistics
software, version 19.0 Data were analyzed using Pearson
correlation analysis, one-way ANOVA, and normality
tests. Results are expressed as the mean ± SD. P < 0.05 was
considered statistically significant in all analyses.
3. Results
3.1. Characteristics of patients
In this study, 200 liver sections were obtained from 200
patients with HBV undergoing surgical resection between
January 2013 and July 2016 in the West China Hospital of
Sichuan University.
The histological stage of fibrosis was scored using Ishak
criteria and 49 patients had no significant fibrosis (Ishak
score 0–2), 101 patients had significant fibrosis (Ishak
score 3–6), 101 patients had no cirrhosis (Ishak score 0–4),
and 49 patients had cirrhosis (Ishak score 5–6).
In a comparison between the nonsignificant fibrosis
group and significant fibrosis group, patients in the
significant fibrosis group were older than those in
the nonsignificant fibrosis group and the difference
was statistically significant (P < 0.01). The significant
fibrosis group had higher levels of ALT and AST than
the nonsignificant fibrosis group (P < 0.05 and P < 0.01,
respectively). The nonsignificant fibrosis group had a
higher PLT count than the significant fibrosis group (P
< 0.01). There was no difference in the sex ratio between
the two groups. In a comparison between the noncirrhotic
group and cirrhotic group, the noncirrhotic group had
a higher PLT count (P < 0.01) and the cirrhotic group
had higher levels of ALT and AST (P < 0.01). There
were no differences in the sex ratio and age between the
two groups. However, males were predominant in each
subgroup (Table).

3.2. Detection of PK2 and CD68 in liver sections
CD68- and PK2-positive cells were large, stellate- or
pyramid-shaped, and were mainly found lining sinusoidal
vessels in the liver (Figure 1). PK2 was also found to be
positive in monocyte/macrophage cells in inflammatory
areas (Figure 2). PK2-positive cells were morphologically
similar to resident macrophages (KCs). In hepatic
sinusoids, PK2-positive cells were also mostly CD68positive, but not vice versa. It is noteworthy that in this
study PK2 was not always expressed in CD68-positive cells
(Figure 3).
In the 200 samples, the expression level of both CD68
and PK2 varied with Ishak score (Figure 4). CD68 and PK2
shared a similar trend in expression during the progression
of fibrosis. The expression of CD68 and PK2 peaked at
the Ishak score of 2 and before that both CD68 and PK2
expression increased. However, after the peak, both CD68
and PK2 expressions decreased and eventually they were
barely detected in sections of HCC tissues. The change in
expression level of PK2 preceded that of CD68 (Figures 5
and 6).
3.3. Detection of the correlation between CD68 and PK2
in different fibrosis scoring systems
At an Ishak score of 0 or 1, no correlation between
the expression levels of CD68 and PK2 was observed.
However, the expression levels of CD68 and PK2 showed a
correlation at Ishak scores of 2 to 6 with R(2) = 0.541, P <
0.01; R(3) = 0.442, P < 0.05; R(4) = 0.490, P < 0.01; R(5) =
0.595, P < 0.01; R(6) = 0.561, P < 0.01 (Figure 7).
At a METAVIR score of 0 or 1, no correlation between
the expression levels of CD68 and PK2 was observed. The
expression levels of CD68 and PK2 showed a correlation at
METAVIR scores of 2 to 4 with R(2) = 0.541, P < 0.01; R(3)
= 0.560, P < 0.01; R(4) = 0.561, P < 0.01 (Figure 8).
At a Knodell score of 0, no correlation between the
expression levels of CD68 and PK2 was observed. The
expression levels of CD68 and PK2 showed a correlation

Table. Characteristics of patients.

Variables

Total
(n = 200)

Nonsignificant
fibrosis: Ishak score
0–2 (n = 49)

Significant fibrosis
Ishak score
3–6 (n = 101)

No cirrhosis:
Ishak score
0–4 (n = 101)

Cirrhosis:
Ishak score
5–6 (n = 49)

Age, years

50.5 ± 13.2

42.8 ± 15.0

53.0 ± 11.4

49.2 ± 14.6

52.0 ± 10.1

Male/female

153/47

34/15

80/21

72/29

42/7

ALT (U/L)

52.6 ± 83.6

31.6 ± 14.1

50.5 ± 55.4

34.4 ± 17.7

64.8 ± 74.4

AST (U/L)

53.5 ± 68.3

28.2 ± 16.4

47.8 ± 36.4

35.1 ± 26.6

54.4 ± 39.6

PLT (109/L)

147.9 ± 64.3

192.6 ± 46.3

150.0 ± 59.8

184.0 ± 52.0

122.6 ± 51.0

ALT: Alanine aminotransferase; AST: aspartate aminotransferase; PLT: platelets.
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Figure 1. CD68-positive cells and PK2-positive cells in hepatic
sinusoid: A) CD68-positive cells in hepatic sinusoid; B) PK2positive cells in hepatic sinusoid.

Figure 2. Expression of PK2 in monocyte/macrophage cells in
the inflammatory area. PK2 was also positive in some monocyte/
macrophage cells in the inflammatory area.

at Knodell scores of 1, 3, and 4 with R(1) = 0.541, P < 0.05;
R(3) = 0.560, P < 0.01; R(4) = 0.561, P < 0.01 (Figure 9).
Thus, the expression levels of CD68 and PK2 did show
a correlation in the three fibrosis scoring systems. It should
be pointed out that when the expression levels changed,
the change in PK2 expression tended to occur before the
change in CD68 expression level.

also has high risks due to its relative lack of sensitivity
(10,27–29).
Innate immune cells contribute to the pathogenesis of
hepatic fibrosis (3,17,30). Previous studies revealed that, in
agreement with the unidirectional irreversible process of
liver fibrosis, hepatic macrophages had dual functions in
experimental liver fibrosis (3,5,6,31).
KCs as liver-resident macrophage cells have a
proinflammatory M1 phenotype and a profibrogenic M2
phenotype and function according to disease kinetics and
environmental cues (4–6,11,32).
During injury, the M1 phenotype initiates the response
to injury by rapidly producing proinflammatory cytokines
and chemokines, including IL-1β, TNF-α, interferon-γ
(IFN-γ), ROS, NO, CCL2, and CCL5 (5–8,11,32,33). In
contrast to the M1 phenotype, the M2 phenotype exhibits
potent antiinflammatory activity and promotes wound
healing and fibrosis (4,6,32). These cells also antagonize
the proinflammatory activity of the M1 phenotype by
releasing IL-10, resistin-like molecule-α (RELM-α),
chitinase-like protein, programmed death ligand-2
(PDL-2), and arginase I (ARG I), helping to resolve
inflammation and initiate the wound-healing response

4. Discussion
Fibrogenesis is an innate response of the liver to chronic
injury, and of all common etiologies of fibrogenesis, CHB
is a main etiology in China (2). With protracted damage
caused by CHB infection, sustained fibrogenesis results in
scar tissue formation in the liver, which generally leads to
cirrhosis, resulting in mortality and morbidity (1,2).
A growing recognition that cirrhosis may be reversible
renders fibrosis and cirrhosis amenable to treatment (3–5).
It is expected that efficient antifibrotic therapy can rebuild
the normal liver accompanied by the restoration of liver
function and regression of clinical manifestations (26).
Thus, efficient antifibrotic therapies are urgently needed.
Unfortunately, to date, few antifibrotic agents are available
(10). Antifibrotic treatment has enormous potential but
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Figure 3. The distribution features of CD68-positive cells and PK2-positive cells: A) distribution
of CD68-positive cells; B) distribution of PK2-positive cells. CD68-positive and PK2-positive
cells: black arrows; CD68-positive but PK2-negative cells: red arrows.

and tissue homeostasis (6,11,34–39). M2 phenotypederived TGFβ1, PDGF, tissue inhibitors of matrix
metalloproteinases (TIMPs), and connective tissue growth
factor (CTGF) activate the transformation of fibroblasts
into myofibroblasts to stimulate the synthesis of ECM
and induce the expression of TIMPs (6,11,34,40). On the
other hand, the M2 phenotype can express mediators that
induce apoptosis of myofibroblasts and serve as antigenpresenting cells (APCs) to promote antigen-specific TH2
and Treg cell responses, resulting in the promotion of
wound healing while limiting the development of fibrosis
(41–43).
PK2 belongs to a novel family of secreted proteins named
prokineticins, which are characterized by an identical
amino acid terminal sequence of AVITGA and a ten-
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cysteine residue sequence (14,17,44). PK2 was previously
demonstrated to play an important role in angiogenesis,
reproduction, carcinogenesis, and survival of neurons as
well as the secretion of hypothalamic hormones, circadian
rhythms, and the modulation of feeding (14–20). New
evidence shows that PK2 is expressed by bone marrow
cells and circulating leukocytes (21,45,46). In addition,
PK2 was shown to directly promote survival, mobilization,
and differentiation of granulocytic and monocytic lineages
(14). PK2 is a potent chemoattractant for monocytes
and macrophages and is able to stimulate the release
of proinflammatory cytokines from macrophages and
monocytes (15,21). In this study, PK2 was expressed
in both KCs and infiltrating monocytes/macrophages.
Taken together, these findings suggest that PK2 may be
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Figure 4. The expression level of CD68 and PK2 in sections (400×). The CD68 and PK2 immunoreactivity in
tissue sections was considered negative when no positive cells were stained, weak when fewer than 30% of the
cells were positive, moderate when 30%–60% of the cells were positive, and strong when more than 60% of
cells were stained as positive. The frequency of staining was thus evaluated as 0, 1+, 2+, and 3+ for no, weak,
moderate, and strong immunoreactivity, respectively. The intensity of staining was similarly evaluated as 0, 1+,
2+, and 3+ for no, weak, medium, and strong staining, respectively.

a component of the role that cytokines-chemokines play
in fibrogenesis, which is completed by the initiation of
KCs and maintained by the subsequent recruitment of
monocytes/macrophages.
KCs act in a highly dynamic and complex way to
maintain homeostasis in the liver (47). As the liver is
constantly at risk of exposure to antigens and bacterial

endotoxins, the liver’s immune system has developed many
mechanisms to avoid ‘accidental’ activation (6). To achieve
this, KCs assist in maintaining immunological tolerance
and in establishing an antiinflammatory microenvironment
(6,11,34). On the other hand, KCs can respond to liver
injury rapidly and initiate the recruitment of monocytes
in both acute and chronic liver injuries and the dramatic
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Figure 5. The semiquantitative analysis of CD68 in liver tissue.
IHC: Immunohistochemistry; F0–F6: fibrosis tissue scored
based on Ishak scoring system; HCC: hepatocellular carcinoma.
The semiquantitative analysis of CD68 was done by IHC. The
mean expression level of CD68 varied among groups. *: P < 0.05,
indicating that there was a significant difference.

Figure 6. The semiquantitative analysis of PK2 in liver tissue.
IHC: Immunohistochemistry; F0–F6: fibrosis tissue scored
based on Ishak scoring system; HCC: hepatocellular carcinoma.
The semiquantitative analysis of PK2 was done by IHC. The
mean expression level of PK2 varied among groups. *: P < 0.05,
indicating that there was a significant difference.

expansion of the KC population due to the massive influx of
monocytes participating in the pathological progression of
injury (6,11,12). PK2 expression in infiltrating monocyte/
macrophage cells was also observed in this study. The
efficient and accurate behavior of KCs is implemented
by the divergence of polarization, namely M1 and M2
(11). There are differences between M1 and M2 in the
activation pathway; proinflammatory M1 is induced by
lipopolysaccharide or IFN-γ, while antiinflammatory
and immunosuppressive M2 is induced by IL-4 and IL13 (6). Studies have demonstrated that PK2 can modulate
the phagocytic capacity of macrophages irrespective of
the maturity and activation of macrophages, and, once
stimulated by PK2, both infiltrating macrophages and
KCs show chemotaxis and secrete cytokines in order to
orchestrate the innate immune system and respond to
injury (3,5,6,11).
When considering the potential cytokine activity of
PK2 and its distribution in this study, it is reasonable to
assume that PK2 is related to the function of KCs, or in
other words the polarization state of KCs during liver
injury.

In this study, the semiquantitative analysis of both
CD68 and PK2 revealed that KCs show an initial increase
and a gradual decrease in PK2 expression during fibrosis
progression and PK2 is barely detected in HCC, which
may be related to inflammatory activity and fibrosis. We
demonstrated that PK2 correlated with the number of KCs
during fibrogenesis. The change in PK2 expression tended
to precede the change in the number of KCs and it was
confirmed in previous studies that PK2 participates in
modulating the number of KCs. In this study, PK2 showed
increased and then decreased expression in KCs in the
later stage of fibrosis, which resulted in the inhibition
of chemotaxis and infiltration of monocytes and may
consequently lead to inhibition of the M1 phenotype. It
follows that with an imbalance between proinflammatory
M1 and antiinflammatory and profibrotic M2, the synthesis
of ECM surpasses decomposition and consequently
protracted fibrogenesis leads to cirrhosis.
In conclusion, we can speculate that it may be the M1
phenotype that is modulated by PK2 during liver injury.
However, this speculation requires further study. There
is no doubt that macrophages are flexible and can switch
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Figure 7. The correlation between CD68 and PK2 in the Ishak
scoring system. IHC: Immunohistochemistry; CD68 and PK2
shared a similar trend in expression during the progression of
fibrosis. There existed a correlation between CD68 and PK2 in
the Ishak scoring system. *: P < 0.05, indicating that there was a
significant difference.

Figure 8. The correlation between CD68 and PK2 in the
METAVIR scoring system. IHC: Immunohistochemistry;
CD68 and PK2 shared a similar trend in expression during the
progression of fibrosis. There existed a correlation between CD68
and PK2 in the METAVIR scoring system. *: P < 0.05, indicating
that there was a significant difference.

Figure 9. The correlation between CD68 and PK2 in the Knodell scoring system. IHC:
Immunohistochemistry; CD68 and PK2 shared a similar trend in expression during
the progression of fibrosis. There existed a correlation between CD68 and PK2 in the
Knodell scoring system. *: P < 0.05, indicating that there was a significant difference.
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from one functional phenotype to another in response to
variable signals in the microenvironment in order to exert
their pro- and antiinflammatory and pro- and antifibrotic
effects. PK2, as a cytokine expressed by KCs in the liver,
plays a key role in modulation of the activity of KCs. This
study determined the correlation between PK2 and the
number of KCs during the progression of liver fibrosis
in patients with HBV based on the Ishak scoring system.
However, it should be noted that the modulation of PK2
on KCs is not exclusive, as the activity of KCs can be
modulated by other mechanisms. Nevertheless, it is the

important effect of PK2 on the activity of KCs that provides
new insights into the potential for therapeutic strategies for
fibrosis. PK2 may be a new therapeutic target. A change in
PK2 via exogenous drugs constitutes a promising strategy
for the treatment of liver fibrosis in patients with CHB.
Acknowledgment
This study was funded in full by “Science and Technology
Support Plan, Department of Technology, Sichuan
Province”, Grant Number 2012SZ0020.

References
1.

Fattovich G, Bortolotti F, Donato F. Natural history of chronic
hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.

2.

Croagh CM, Lubel JS. Natural history of chronic hepatitis B:
phases in a complex relationship. World J Gastroentero 2014;
20: 10395-10404.

3.

Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver
fibrosis and repair: immune regulation of wound healing in a
solid organ. Nat Rev Immunol 2014; 14: 181-194.

4.

Kisseleva T, Brenner DA. The phenotypic fate and functional
role for bone marrow-derived stem cells in liver fibrosis. J Hepatol 2012; 56: 965-972.

5.

Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 10281040.

6.

Ju C, Tacke F. Hepatic macrophages in homeostasis and liver
diseases: from pathogenesis to novel therapeutic strategies.
Cell Mol Immunol 2016; 13: 316-327.

7.

Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115:
209-218.

14.

Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P,
Screpanti I, Balboni G, Salvadori S, Sacerdote P, Negri L. The
chemokine Bv8/prokineticin 2 is up-regulated in inflammatory
granulocytes and modulates inflammatory pain. P Natl Acad
Sci USA 2009; 106: 14646-14651.

15.

Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri
L, Sacerdote P. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of
mouse macrophages. Br J Pharmacol 2006; 147: 225-234.

16.

Melchiorri D, Bruno V, Besong G, Ngomba RT, Cuomo L, De
Blasi A, Copani A, Moschella C, Storto M, Nicoletti F et al. The
mammalian homologue of the novel peptide Bv8 is expressed
in the central nervous system and supports neuronal survival
by activating the MAP kinase/PI-3-kinase pathways. Eur J
Neurosci 2001; 13: 1694-1702.

17.

Monnier J, Piquet-Pellorce C, Feige JJ, Musso O, Clement B,
Turlin B, Theret N, Samson M. Prokineticin 2/Bv8 is expressed
in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma. World J Gastroentero 2008; 14: 11821191.

18.

Negri L, Lattanzi R, Giannini E, Colucci MA, Mignogna G,
Barra D, Grohovaz F, Codazzi F, Kaiser A, Kreil G et al. Biological activities of Bv8 analogues. Br J Pharmacol 2005; 146:
625-632.

8.

Wells RG. Mechanisms of liver fibrosis: new insights into an
old problem. Drug Discov Today 2006; 3: 489-495.

9.

Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis.
Best Pract Res Clin Gastroenterol 2011; 25: 195-206.

19.

10.

Friedman SL. Liver fibrosis -- from bench to bedside. J Hepatol
2003; 38 (Suppl. 1): S38-53.

Negri L, Lattanzi R, Giannini E, Melchiorri P. Bv8/Prokineticin
proteins and their receptors. Life Sci 2007; 81: 1103-1116.

20.

11.

Tacke F, Zimmermann HW. Macrophage heterogeneity in liver
injury and fibrosis. J Hepatol 2014; 60: 1090-1096.

Dorsch M, Qiu Y, Soler D, Frank N, Duong T, Goodearl A,
O’Neil S, Lora J, Fraser CC. PK1/EG-VEGF induces monocyte
differentiation and activation. J Leukoc Biol 2005; 78: 426-434.

12.

Elsegood CL, Chan CW, Degli-Esposti MA, Wikstrom ME,
Domenichini A, Lazarus K, van Rooijen N, Ganss R, Olynyk
JK, Yeoh GC. Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver
regeneration. Hepatology 2015; 62: 1272-1284.

21.

LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. P Natl
Acad Sci USA 2004; 101: 16813-16818.

22.

Goodman ZD. Grading and staging systems for inflammation
and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598607.

13.

60

Monnier J, Samson M. Cytokine properties of prokineticins.
FEBS J 2008; 275: 4014-4021.

LIU et al. / Turk J Med Sci
36.

Sutherland TE, Maizels RM, Allen JE. Chitinases and chitinaselike proteins: potential therapeutic targets for the treatment of
T-helper type 2 allergies. Clin Exp Allergy 2009; 39: 943-955.

37.

Pesce JT, Ramalingam TR, Wilson MS, Mentink-Kane MM,
Thompson RW, Cheever AW, Urban JF Jr, Wynn TA. Retnla
(relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog 2009; 5: e1000393.

38.

Reese TA, Liang HE, Tager AM, Luster AD, Van Rooijen N,
Voehringer D, Locksley RM. Chitin induces accumulation in
tissue of innate immune cells associated with allergy. Nature
2007; 447: 92-96.

Chuang HM, Su HL, Li C, Lin SZ, Yen SY, Huang MH, Ho LI,
Chiou TW, Harn HJ. The role of butylidenephthalide in targeting the microenvironment which contributes to liver fibrosis
amelioration. Front Pharmacol 2016; 7: 112.

39.

London A, Itskovich E, Benhar I, Kalchenko V, Mack M, Jung
S, Schwartz M. Neuroprotection and progenitor cell renewal
in the injured adult murine retina requires healing monocytederived macrophages. J Exp Med 2011; 208: 23-39.

27.

Weiskirchen R. Hepatoprotective and anti-fibrotic agents: it’s
time to take the next step. Front Pharmacol 2015; 6: 303.

40.

28.

Samuel CS, Summers RJ, Hewitson TD. Antifibrotic actions of
serelaxin - new roles for an old player. Trends Pharmacol Sci
2016; 37: 485-497.

Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T. Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5. J Clin Invest 2008;
118: 924-934.

41.

Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500-503.

42.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M,
Moore KW, O’Garra A. IL-10 acts on the antigen-presenting
cell to inhibit cytokine production by Th1 cells. J Immunol
1991; 146: 3444-3451.

43.

Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk A, Ottenhoff TH. Human anti-inflammatory macrophages induce Foxp3+GITR+CD25+ regulatory T cells,
which suppress via membrane-bound TGFβ-1. J Immunol
2008; 181: 2220-2226.

44.

Zhou QY. The prokineticins: a novel pair of regulatory peptides. Mol Interv 2006; 6: 330-338.

45.

Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D,
Bais C, Peale FV, van Bruggen N et al. Bv8 regulates myeloidcell-dependent tumour angiogenesis. Nature 2007; 450: 825831.

46.

Zhong C, Qu X, Tan M, Meng YG, Ferrara N. Characterization
and regulation of bv8 in human blood cells. Clin Cancer Res
2009; 15: 2675-2684.

47.

Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013; 14: 996.

23.

Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna
KV, Little LD, Qiu P, Bertelsen AH, Watson M. ITPA gene variants protect against anaemia in patients treated for chronic
hepatitis C. Nature 2010; 464: 405-408.

24.

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA,
Conjeevaram HS, Lok AS. A simple noninvasive index can
predict both significant fibrosis and cirrhosis in patients with
chronic hepatitis C. Hepatology 2003; 38: 518-526.

25.

Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou
K, Lah TT. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 2009; 29: 3269-3279.

26.

29.

Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol
Interact 2011; 193: 225-231.

30.

Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis.
5. Novel insights into liver fibrosis. Am J Physiol Cell Physiol
2013; 305: C789-799.

31.

Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host
defense and liver disease. Liver Int 2006; 26: 1175-1186.

32.

Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MPJ,
Donners MMPC. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis 2014; 17: 109-118.

33.

Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J
Clin Invest 2013; 123: 1887-1901.

34.

Heymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M,
Ergen C, Niemietz P, Martin C, van Rooijen N, Ochando JC,
Randolph GJ et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 2015; 62:
279-291.

35.

Herbert DR, Orekov T, Roloson A, Ilies M, Perkins C, O’Brien
W, Cederbaum S, Christianson DW, Zimmermann N, Rothenberg ME et al. Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. J Immunol
2010; 184: 6438-6446.

61

